Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cinclus Pharma Holding AB ( (SE:CINPHA) ) has shared an update.
Cinclus Pharma has entered a strategic alliance with Zentiva to commercialize and manufacture linaprazan glurate in Europe, covering all EEA member states, the UK, and Switzerland. The deal, valued at EUR 220 million, includes upfront and milestone payments, and positions Cinclus Pharma to benefit from Zentiva’s extensive commercial reach and operational strength, enhancing its market presence and capturing significant global value.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of gastric acid-related diseases. Their primary product, linaprazan glurate, is a next-generation potassium-competitive acid blocker designed to treat severe erosive gastroesophageal reflux disease (eGERD).
Average Trading Volume: 68,044
For a thorough assessment of CINPHA stock, go to TipRanks’ Stock Analysis page.